KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Non-Current Assets: 2020-2024

Historic Other Non-Current Assets for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $8.8 million.

  • Recursion Pharmaceuticals' Other Non-Current Assets rose 121.16% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 121.16%. This contributed to the annual value of $8.8 million for FY2024, which is 33.13% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $8.8 million for FY2024, which was up 33.13% from $6.6 million recorded in FY2023.
  • Recursion Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $8.8 million during FY2024, with a 5-year trough of $3.0 million in FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Other Non-Current Assets averaged around $7.8 million, with its median value being $7.9 million (2022).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Other Non-Current Assets skyrocketed by 185.47% in 2021 and then declined by 16.30% in 2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $3.0 million in 2020, then soared by 185.47% to $8.7 million in 2021, then declined by 8.77% to $7.9 million in 2022, then fell by 16.30% to $6.6 million in 2023, then skyrocketed by 33.13% to $8.8 million in 2024.